Loading
MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. Its programs include MN-001, MN-166 neurology diseases, and MN-221 respiratory diseases. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.
Latest quote
¥274
+¥16.00 · +6.20%
Regular session · JST · Market data may be delayed.
MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. Its programs include MN-001, MN-166 neurology diseases, and MN-221 respiratory diseases. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.
Day range
Current ¥274
52-week range
Current ¥274
Regular session · JST · Market data may be delayed.
MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. Its programs include MN-001, MN-166 neurology diseases, and MN-221 respiratory diseases. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.
Day range
Current ¥274
52-week range
Current ¥274
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 409.66K USD | — | 1.01M USD | — | 4.04M USD |
| Cost of goods sold | 398.71K USD | 21.08K USD | 20.47K USD | 214.8K USD | — |
| Gross profit | 10.95K USD | −21.08K USD | 988.18K USD | −214.8K USD | 4.04M USD |
| Research and development | 7.13M USD | 7.17M USD | 5.69M USD | 9.03M USD | 8.52M USD |
| Selling, general, and administrative | 6.16M USD | 5.48M USD | 5.29M USD | 5.55M USD | 5.72M USD |
| Operating expenses | 13.29M USD | 12.65M USD | 10.97M USD | 14.58M USD | 14.24M USD |
| Interest income | 1.3M USD | 1.67M USD | 1.85M USD | 818.74K USD | 143.76K USD |
| Depreciation and amortization | 193.78K USD | 21.08K USD | 20.47K USD | 214.8K USD | 26.17K USD |
| Operating income | −13.28M USD | −12.68M USD | −9.99M USD | −14.79M USD | −10.23M USD |
| Net income | −12M USD | −11.05M USD | −8.65M USD | −14.23M USD | −10.14M USD |
Company facts updated Sep 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Nov 1, 2006 | 1:10 | — | — |
Effective Nov 1, 2006
1:10
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
